A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL

Authors: , Annette M. Staiger, , Michael Altenbuchinger, Marita Ziepert, Christian Kohler, Heike Horn, Michael Huttner, Katrin S. Hüttl, Gunther Glehr, Wolfram Klapper, Monika Szczepanowski, Julia Richter, Harald Stein, Alfred C. Feller, Peter Möller, Martin-Leo Hansmann, Viola Poeschel, Gerhard Held, Markus Loeffler, Norbert Schmitz, Lorenz Trümper, Tobias Pukrop, Andreas Rosenwald, German Ott, Rainer Spang

Published: 2019-09-17

DOI: 10.1038/s41375-019-0573-y

Source: Full article

---

Abstract

No abstract found.